MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

University of Colorado Denver (CU Denver)

Status: Active, not recruiting

Conditions: Diastolic Dysfunction

Treatments: Dietary Supplement: Placebo, then MITOQUINOL MESYLATE; Dietary Supplement: MITOQUINOL MESYLATE then placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03586414

17-1782

Details and patient eligibility

About

In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.

Full description

Heart failure affects over 5 million American adults and the risk of heart failure increases with age. Diastolic function typically declines with age. Targeting age-related causal factors leading to the decline in diastolic function in both women and men is a major public health initiative. In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function in older adults. As an exploratory aim, the investigators will determine whether there are differences between men and women in response to this supplementation.

Enrollment: 31 patients

Sex: All

Ages: 50 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. 50 - 75 years of age
2. sedentary-to-recreationally active (<3 days of vigorous exercise);
3. nonsmokers;
4. healthy, as determined by medical history, physical examination, standard blood chemistries.

Exclusion criteria

1. history of cancer
2. history of cardiovascular disease
3. unwilling or unable to take MitoQ supplement;
4. taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications (e.g., aspirin);
5. taking sex hormone therapy
6. presence of menses within last 1 year;
7. taking any other medications (e.g., antihypertensives, lipid lowering medications) that would interact with MitoQ or impact CV function

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

31 participants in 2 patient groups

A: 'MITOQUINOL MESYLATE then placebo

Experimental group

Description:

'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.

Treatment:

Dietary Supplement: MITOQUINOL MESYLATE then placebo

B: Placebo then 'MITOQUINOL MESYLATE'

Experimental group

Description:

Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'

Treatment:

Dietary Supplement: Placebo, then MITOQUINOL MESYLATE